Missouri Judge Gives Final Approval to Bayer-Monsanto Roundup Class Settlement

BAYRY

·

A Missouri judge has granted final approval to Bayer and Monsanto’s nationwide Roundup class settlement, clearing the way for a program that caps U.S. payments at up to $7.25 billion for people who say they developed non-Hodgkin lymphoma after exposure to the weedkiller.

Judge Timothy J. Boyer of the Circuit Court for the City of St. Louis approved the deal Friday in King v. Monsanto Co. The class covers people exposed to Roundup products in the United States before Feb. 17, 2026, who already had a diagnosis of non-Hodgkin lymphoma or who are diagnosed within a 16-year claims window after the settlement takes effect. The approval is still subject to appeal, and if appeals are filed, most payments and claims processing will be paused until they are exhausted.

The settlement is structured as declining, capped annual payments over as long as 21 years, and the $7.25 billion ceiling includes payments already made under the program. Reported average award amounts vary by tier and claimant profile, from about $10,000 to $165,000. But the deal does not automatically end all Roundup litigation: It is a Missouri state-court nationwide class program, and federal cases in the Roundup multidistrict litigation generally are excluded unless a claimant dismisses that case and opts into the class program.

The order marks one of the largest mass-tort settlements of its kind. Boyer described the average individual awards as “fair and adequate” and the overall dollar commitment as “among the largest in the history of mass tort personal-injury class action settlements,” according to AP’s report on the order. AP also reported that roughly 65,000 claims were pending in state and federal courts when the deal was approved. The final approval order included $600 million in attorneys’ fees, AP reported.

“The Court’s final approval is a decisive milestone in the company’s strategy to mitigate the risks of both pending and future Roundup™ litigation,” Bayer CEO Bill Anderson said in a company press release. Christopher A. Seeger, court-appointed counsel for cancer patients, said via AP that “Today’s final approval order delivers guaranteed compensation to Roundup cancer victims who have waited more than a decade for justice.”

Bayer inherited the Roundup litigation when it bought Monsanto and in 2020 announced agreements worth $10.1 billion to $10.9 billion to resolve much of the earlier case inventory. Even after those deals, substantial numbers of cases remained. Earlier this year, when Bayer announced the proposed class settlement, it said it would increase litigation provisions from 7.8 billion euros to 11.8 billion euros as part of its planning for Roundup resolutions.

The settlement also arrives after a major legal shift. In June 2026, the U.S. Supreme Court ruled in Monsanto Co. v. Durnell that federal pesticide law pre-empts certain state-law failure-to-warn claims, narrowing one major path for plaintiffs. Against that backdrop, the Missouri approval gives Bayer a clearer framework for addressing both existing and future claims, even though it does not wipe out all pending lawsuits.

Glyphosate, the active ingredient associated with Roundup, has been the subject of a long-running scientific and regulatory dispute: the International Agency for Research on Cancer classified it in 2015 as “probably carcinogenic,” while the U.S. Environmental Protection Agency has said glyphosate products are not likely carcinogenic when used as directed.

For Bayer, the ruling reduces a major legal overhang. For claimants, though, compensation still depends on the settlement becoming final after any appeals.

Tags: #bayer, #roundup, #class-action, #glyphosate

Stocks: BAYRY